Dr Flora Hui has a particular interest in innovative methods to improve patient outcomes in optometry and ophthalmology and neuroprotectants for treating glaucoma.

She completed a Master of Philosophy and Doctor of Philosophy in fundamental sciences, concentrating on animal models of glaucoma and using the retina as a biomarker for the brain. She moved into glaucoma clinical research at CERA, focusing on developing novel clinical tools that measure retinal structure and function, to shorten the timeframe to detect glaucoma progression.

Dr Flora Hui conducted a world-first clinical trial investigating high-dose nicotinamide (Vitamin B₃) as a neuroprotectant in human glaucoma, showing that nicotinamide could lead to early and significant improvements to visual function. In addition, building upon her preclinical work, she was involved in a landmark study investigating the use of hyperspectral retinal imaging to differentiate people who were diagnosed with Alzheimer’s disease.